Swiss pharmaceutical leader Sandoz has launched a major expansion in Slovenia, beginning construction on a €400 million biosimilars plant near Ljubljana airport.
Set to open within three years, the facility will create more than 260 new jobs by 2029 and become part of a vertically integrated biosimilars supply chain spanning the country.
This is just one in a series of strategic investments: a €90 million R&D centre is underway in Ljubljana, and a €400 million site for active pharmaceutical ingredients is rising in Lendava.
Altogether, Sandoz will invest over €1 billion in Slovenia by 2029—cementing its role as the country’s largest foreign investor.
For Slovenia, the move signals growing industrial strength and a deepening role in Europe’s pharmaceutical autonomy.
Sandoz cited the nation’s engineering expertise, stability, and forward-thinking workforce as decisive factors.
Government officials view the investment as a vote of confidence in Slovenia’s public institutions and long-term potential.